The fucosidosis therapeutic market — treatments for an ultra-rare, autosomal recessive lysosomal storage disorder caused by mutations in the FUCA1 gene that lead to alpha-L-fucosidase enzyme deficiency and progressive neurodegeneration — remains one of the smallest disease-specific therapeutic categories in rare disease pharma, with the Fucosidosis Therapeutic Market reflected...